Anesthesia, CaudalPhase 3NCT05133687
The Hemodynamic Effects of Different Volumes of Bupivacaine 0.25% Caudal Blocks in Pediatrics Undergoing Lower Abdominal Surgeries as Measured by Electrical Cardiometry
A Phase 3 study testing Bupivacaine Hydrochloride in people with Anesthesia, Caudal and Pediatrics, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
This randomized, controlled study is designed to estimate the effects of different volumes of plain bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry. Read more about this study
- Who is it for?
- Ages 1 year to 8 years
- Conditions the study is for
- Anesthesia, Caudal, Pediatrics
- What is being tested?
- Bupivacaine Hydrochloride
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 105 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Nov 2021to 30 May 2022
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 8 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- All pediatrics ASA I\&II aged 1-8 years undergoing elective lower abdominal surgeries.
Who cannot join
- ASA ≥ III. Parents refusal of caudal block. Patients with coagulation disorders (Platelets ≤ 50,000 and/or INR> 1.5). Patients with suspected or proved allergic to local anesthetics. Rash or signs of infection at the injection site. Patients requiring emergency or laparoscopic procedures.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Hemodynamic Effects of Different Volumes of Bupivacaine 0.25% Caudal Blocks in Pediatrics Undergoing Lower Abdominal Surgeries as Measured by Electrical Cardiometry: A Randomized Controlled Study
This randomized, controlled study is designed to estimate the effects of different volumes of plain bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry.
Read the detailed description
Introduction:
Caudal block is one of the most used regional blocks in pediatrics because it is safe and provides efficient and adequate perioperative analgesia for most of the infra-umbilical and lower limb procedures.[1,2] It has been proposed that the cardiovascular effects of neuraxial blocks are less marked in children than in adults because of lower systemic vascular resistance (SVR) in pediatric population.[3] There is a wide range of doses used in caudal block depending on the desired dermatomal level which can range from 0.5ml/kg up to 1.25ml/kg. [1] However, studies assessing effects and safety of different volumes of caudal blocks on different hemodynamic variables are scarce and show conflicting results due to small sample sizes, absence of control groups, retrospective nature, different additives and different methods for measuring the hemodynamics.[4-8] Electrical Cardiometry (EC) estimates cardiac parameters by measuring changes in thoracic electrical bioimpedance during the cardiac cycle using skin electrodes. It has emerged as a new noninvasive tool for assessment of cardiac output with a good accuracy in adult and pediatric anesthesia.[9] The current study is designed to estimate the effects of different volumes of bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry.
Hypothesis:
We hypothesized that different volumes of plain bupivacaine 0.25% caudal block could have direct effects on different hemodynamic parameters in pediatrics undergoing lower abdominal surgeries.
Methods:
The study is a double blinded randomized controlled trial that will be conducted at Abu Al Reesh Children's Hospital, Faculty of Medicine, Cairo University after approval of research and ethics committees.
Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
Randomization will be achieved using a computer-generated sequence. Concealment will be achieved using opaque envelopes.
All children will be anesthetized in accordance with the local policy of pediatric anesthesia unit in Abu El-Reesh pediatric hospital-Cairo university.
After preoperative examination and upon arrival to the operating room heart rate HR, noninvasive blood pressure NBP and oxygen saturation SPO2 will be monitored using standard monitor (drȁger infinity vista XL) before inhalational induction of anesthesia using titration of sevoflurane in oxygen air mixture 60% (starting from 3% up to 8%) until the child is put to sleep. Electrical cardiometry device (ICON; Cardiotonic, Osypka; Berlin, Germany) will be applied to the patient through 4 ECG electrodes at the following sites: (forehead, left side of the neck, left mid-axillary line at the level of xiphoid process and left thigh). Patient's sex, height, and weight will be entered into the device, which is set to estimate cardiovascular parameters at a 20-beat moving average recorded every10 seconds. The ECG electrodes will be placed before induction for cooperative children. Baseline electrical cardiometry (ICON) data (Cardiac output, Cardiac index, Stroke volume, Stroke volume variation, Stroke index, Systemic vascular resistance, Systemic vascular resistance index, ICON, VIC, Thoracic fluid index, Left cardiac work, Systolic time ratio, Pre ejection period, Left ventricular ejection time) will be recorded by averaging 3 sets of data over 30 seconds by an anesthesia resident who is blinded to the children groups.
After securing an intravenous line anesthesia will be completed with 1-2µg/kg of fentanyl and atracurium 0.5 mg/kg to facilitate endotracheal intubation. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.
The concealed envelopes will then be opened by a second anesthesia resident (who will not be involved in patient management) and he will be responsible for preparing and giving the caudal block for the caudal groups as instructed in the envelope.
Children in groups (0.8-G) and (1.2-G) will then be positioned on their right side, and a 22-gauge needle will be aseptically inserted into the caudal epidural space. Bupivacaine 0.25% at a dose of 0.8 ml/kg and 1.2 ml/kg making sure not to exceed a maximum of 2.5 mg/kg will be slowly injected. After repositioning the children on their backs, a 10-min steady-state period without surgical stimulation will be permitted during which a multiple set of measurements will be obtained every 2 minutes (a single set of measurements will be recorded by averaging 3 sets of data over 30 seconds), and surgery will be started after this period. Caudal success will be defined as change of hemodynamics (heart rate and or blood pressure) < 20% of base line parameters to surgical incision without need for additional analgesics or increase of inhalational anesthetics. Patients with caudal failure will be excluded from the study.
In group G the surgery will be started after 10 minutes from the induction of anesthesia where a multiple sets of ICON measurements will be obtained every 2 minutes (a single set of measurements will be recorded by averaging 3 sets of data over 30 seconds), from the previous baseline measurements.
In all groups ICON measurements will be obtained every 10 minutes after start of surgery till the end of surgery.
In all groups HR, NBP, SPO2 and end tidal CO2 will be measured every 2 minutes for 10 minutes after induction of anesthesia then every 10 minutes till the end of surgery.
All children will receive a loading dose of 10 ml/kg of lactated ringer solution over 10 minutes after induction of anesthesia and will be maintained on 3 ml/kg/h lactated ringer solution.
- Conditions
- Anesthesia, Caudal, Pediatrics
- Being tested
- Bupivacaine Hydrochloride
- Keywords
- pediatrics, caudal anesthesia, hemodynamics, electrical cardiometry, bupivacaine 0.25%
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bupivacaine HydrochlorideDrug
Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G).
| Study group | Role | What they receive |
|---|---|---|
| Group (0.8-G) | Experimental | This group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% Receives: Drug: Bupivacaine Hydrochloride |
| Group (1.2-G) | Experimental | This group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% Receives: Drug: Bupivacaine Hydrochloride |
| Group G | Active comparator | This group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure. Receives: Drug: Bupivacaine Hydrochloride |
What is being measured
The primary outcome is the main question the study is designed to answer.
The percentage of change from the baseline measurement of the cardiac index CI 10 minutes after successful caudal block.
Measured: 10 minutes after caudal block.
Secondary outcomes (4)
Electrical cardiometry cardiac index
Measured: 30 minutes
mean ABP
Measured: 1-2 hours
Incidence of complications: block failure, bradycardia (HR < 80/min) , hypotension (blood pressure <20% of base line) and local anesthesia systemic toxicity (LAST)
Measured: 1-2 hours
heart rate
Measured: 1-2 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2021
- Study start15 Nov 2021
- Primary completion30 May 2022
- Study completion30 May 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anesthesia, CaudalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 105 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Khaled Abdelfattah Abdallah Sarhan, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05133687
- Sponsor's protocol ID
- MS-445-2021
- Status last verified
- Jul 2024
- First submitted
- 15 Nov 2021
- Last updated
- 9 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Hemodynamic Effects of Different Volumes of Bupivacaine 0.25% Caudal Blocks in Pediatrics Undergoing Lower Abdominal Surgeries as Measured by Electrical Cardiometry: A Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT05133687
- Acronym / sponsor ID
- MS-445-2021
- Conditions
- Anesthesia, Caudal, Pediatrics
- Keywords
- pediatrics, caudal anesthesia, hemodynamics, electrical cardiometry, bupivacaine 0.25%
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 105 participants (actual)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 15 Nov 2021 (actual)
- Primary completion
- 30 May 2022 (actual)
- Study completion
- 30 May 2022 (actual)
- First posted
- 24 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized, controlled study is designed to estimate the effects of different volumes of plain bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry.
Detailed description
Introduction:
Caudal block is one of the most used regional blocks in pediatrics because it is safe and provides efficient and adequate perioperative analgesia for most of the infra-umbilical and lower limb procedures.[1,2] It has been proposed that the cardiovascular effects of neuraxial blocks are less marked in children than in adults because of lower systemic vascular resistance (SVR) in pediatric population.[3] There is a wide range of doses used in caudal block depending on the desired dermatomal level which can range from 0.5ml/kg up to 1.25ml/kg. [1] However, studies assessing effects and safety of different volumes of caudal blocks on different hemodynamic variables are scarce and show conflicting results due to small sample sizes, absence of control groups, retrospective nature, different additives and different methods for measuring the hemodynamics.[4-8] Electrical Cardiometry (EC) estimates cardiac parameters by measuring changes in thoracic electrical bioimpedance during the cardiac cycle using skin electrodes. It has emerged as a new noninvasive tool for assessment of cardiac output with a good accuracy in adult and pediatric anesthesia.[9] The current study is designed to estimate the effects of different volumes of bupivacaine 0.25% caudal block on different hemodynamic parameters assessed by electrical cardiometry.
Hypothesis:
We hypothesized that different volumes of plain bupivacaine 0.25% caudal block could have direct effects on different hemodynamic parameters in pediatrics undergoing lower abdominal surgeries.
Methods:
The study is a double blinded randomized controlled trial that will be conducted at Abu Al Reesh Children's Hospital, Faculty of Medicine, Cairo University after approval of research and ethics committees.
Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
Randomization will be achieved using a computer-generated sequence. Concealment will be achieved using opaque envelopes.
All children will be anesthetized in accordance with the local policy of pediatric anesthesia unit in Abu El-Reesh pediatric hospital-Cairo university.
After preoperative examination and upon arrival to the operating room heart rate HR, noninvasive blood pressure NBP and oxygen saturation SPO2 will be monitored using standard monitor (drȁger infinity vista XL) before inhalational induction of anesthesia using titration of sevoflurane in oxygen air mixture 60% (starting from 3% up to 8%) until the child is put to sleep. Electrical cardiometry device (ICON; Cardiotonic, Osypka; Berlin, Germany) will be applied to the patient through 4 ECG electrodes at the following sites: (forehead, left side of the neck, left mid-axillary line at the level of xiphoid process and left thigh). Patient's sex, height, and weight will be entered into the device, which is set to estimate cardiovascular parameters at a 20-beat moving average recorded every10 seconds. The ECG electrodes will be placed before induction for cooperative children. Baseline electrical cardiometry (ICON) data (Cardiac output, Cardiac index, Stroke volume, Stroke volume variation, Stroke index, Systemic vascular resistance, Systemic vascular resistance index, ICON, VIC, Thoracic fluid index, Left cardiac work, Systolic time ratio, Pre ejection period, Left ventricular ejection time) will be recorded by averaging 3 sets of data over 30 seconds by an anesthesia resident who is blinded to the children groups.
After securing an intravenous line anesthesia will be completed with 1-2µg/kg of fentanyl and atracurium 0.5 mg/kg to facilitate endotracheal intubation. Anesthesia will be maintained by using 1-1.5% isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes.
The concealed envelopes will then be opened by a second anesthesia resident (who will not be involved in patient management) and he will be responsible for preparing and giving the caudal block for the caudal groups as instructed in the envelope.
Children in groups (0.8-G) and (1.2-G) will then be positioned on their right side, and a 22-gauge needle will be aseptically inserted into the caudal epidural space. Bupivacaine 0.25% at a dose of 0.8 ml/kg and 1.2 ml/kg making sure not to exceed a maximum of 2.5 mg/kg will be slowly injected. After repositioning the children on their backs, a 10-min steady-state period without surgical stimulation will be permitted during which a multiple set of measurements will be obtained every 2 minutes (a single set of measurements will be recorded by averaging 3 sets of data over 30 seconds), and surgery will be started after this period. Caudal success will be defined as change of hemodynamics (heart rate and or blood pressure) < 20% of base line parameters to surgical incision without need for additional analgesics or increase of inhalational anesthetics. Patients with caudal failure will be excluded from the study.
In group G the surgery will be started after 10 minutes from the induction of anesthesia where a multiple sets of ICON measurements will be obtained every 2 minutes (a single set of measurements will be recorded by averaging 3 sets of data over 30 seconds), from the previous baseline measurements.
In all groups ICON measurements will be obtained every 10 minutes after start of surgery till the end of surgery.
In all groups HR, NBP, SPO2 and end tidal CO2 will be measured every 2 minutes for 10 minutes after induction of anesthesia then every 10 minutes till the end of surgery.
All children will receive a loading dose of 10 ml/kg of lactated ringer solution over 10 minutes after induction of anesthesia and will be maintained on 3 ml/kg/h lactated ringer solution.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Children will be recruited into the trial during pre-operative assessment. Recruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G) to receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% and (Group 1.2-G) to receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% and (Group G) to receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure.
| Arm | Type | Receives |
|---|---|---|
| Group (0.8-G) | Experimental | Drug: Bupivacaine HydrochlorideThis group will receive general anesthesia and caudal block with 0.8 ml/kg of bupivacaine 0.25% |
| Group (1.2-G) | Experimental | Drug: Bupivacaine HydrochlorideThis group will receive general anesthesia and caudal block with 1.2 ml/kg of bupivacaine 0.25% |
| Group G | Active comparator | Drug: Bupivacaine HydrochlorideThis group will receive general anesthesia with local infiltration of the wound or transversus abdominis plan block (TAPB) at the end of the procedure. |
Who may qualify
- Ages
- 1 year to 8 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- All pediatrics ASA I\&II aged 1-8 years undergoing elective lower abdominal surgeries.
Key exclusion criteria (1 listed)
- ASA ≥ III. Parents refusal of caudal block. Patients with coagulation disorders (Platelets ≤ 50,000 and/or INR> 1.5). Patients with suspected or proved allergic to local anesthetics. Rash or signs of infection at the injection site. Patients requiring emergency or laparoscopic procedures.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bupivacaine HydrochlorideRecruited children will be randomly assigned to one of three groups in a 1:1:1 ratio; (Group 0.8-G), (Group 1.2-G) and (Group G). | Drug | Group (0.8-G), Group (1.2-G), Group G |
Primary outcome
The percentage of change from the baseline measurement of the cardiac index CI 10 minutes after successful caudal block.
Time frame: 10 minutes after caudal block.
4 secondary outcomes
Electrical cardiometry cardiac index
Time frame: 30 minutes
mean ABP
Time frame: 1-2 hours
Incidence of complications: block failure, bradycardia (HR < 80/min) , hypotension (blood pressure <20% of base line) and local anesthesia systemic toxicity (LAST)
Time frame: 1-2 hours
heart rate
Time frame: 1-2 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Anesthesia, Caudal
Not yet recruitingPhase 4
Effect of Intravenous Versus Caudal Dexmedetomidine on Perfusion Index and Hemodynamic Responses in Children Undergoing Infraumbilical Surgery
Postoperative Pain, Caudal Anesthesia
RecruitingObservational study
Comparison of Erector Spinae Plane Block and Caudal Block for Postoperative Analgesia in Pediatric Patients Undergoing Orchiopexy: A Prospective Observational Study
Caudal Epidural Anesthesia, Sacral Erector Spinae Plane Block
Not yet recruitingObservational study
Comparison of The Perfusion Index and The Surgical Pleth Index in Detecting The Effectiveness of Caudal Block in Pediatrics
The Success of Caudal Block
Recruiting
Effect of Caudal Block on Urethrocutaneous Fistula After Distal Hypospadias Repair
Hypospadias, Caudal Block
Not yet recruiting
Comparison of Erector Spinae Plane Block and Caudal Block in Pediatric Patients Aged 1 to 8 Years Undergoing Lower Abdominal Surgery
Caudal Epidural Anesthesia, Erector Spinae Plane Block
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Bupivacaine Hydrochloride in people with Anesthesia, Caudal and Pediatrics, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The percentage of change from the baseline measurement of the cardiac index CI 10 minutes after successful caudal block. (time frame: 10 minutes after caudal block.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2024.